Valuation: Neurocrine Biosciences, Inc.

Market Cap 16.76B 14.92B 13.69B 12.44B 23.41B 1,586B 23.92B 163B 65.45B 838B 62.89B 61.54B 2,654B P/E 2026 *
22.6x
P/E 2027 * 16.9x
Enterprise Value 15.08B 13.43B 12.32B 11.19B 21.08B 1,427B 21.53B 147B 58.92B 755B 56.61B 55.4B 2,389B EV / Sales 2026 *
3.86x
EV / Sales 2027 * 3x
Free-Float
99.36%
Yield 2026 *
-
Yield 2027 * -
1 day+0.73%
1 week+13.73%
Current month+13.66%
1 month+15.97%
3 months-0.11%
6 months+26.01%
Current year+17.08%
1 week 143.75
Extreme 143.75
169.53
1 month 132.25
Extreme 132.25
169.53
Current year 122.14
Extreme 122.1375
186.12
1 year 122.14
Extreme 122.1375
186.12
3 years 84.23
Extreme 84.23
186.12
5 years 71.88
Extreme 71.875
186.12
10 years 37.34
Extreme 37.345
186.12
Manager TitleAgeSince
Chief Executive Officer 53 11/10/2024
Director of Finance/CFO 46 01/11/2017
Chief Tech/Sci/R&D Officer 62 08/01/2018
Director TitleAgeSince
Director/Board Member 68 01/01/2008
Director/Board Member 64 01/04/1998
Chairman 78 01/05/2011
Date Insider Type Main position Quantity % Market Cap. Importance
9/28/26 A Other

Chief Technology Officer

348,990 0.3433%
9/14/26 A Sell

Chief Financial Officer

-2,311 0.0023%
9/14/26 A Sell

Executive/Senior Manager

-826 0.0008%
Change 5-day change 1-year change 3-year change Capi.($)
+0.73%+13.73%+16.97%+47.68% 16.76B
+0.61%+10.62%+58.16%+149.73% 1,255B
+3.81%+2.82%+48.35%+82.58% 641B
+3.09%+2.95%+39.10%+108.48% 505B
+1.25%-0.78%+52.56%+66.87% 381B
+3.93%+6.02%+82.28%+45.44% 357B
+2.10%+4.26%+34.93%+61.10% 303B
+1.92%+9.37%+13.43%+36.55% 286B
+3.73%+6.82%+61.48%+77.31% 249B
+4.19%+9.68%+42.96%+113.85% 208B
Average +1.66%+3.94%+45.02%+78.96% 420.2B
Weighted average by Cap. +1.06%+3.94%+50.47%+97.59%

Financials

2026 *2027 *
Net sales 3.9B 3.48B 3.19B 2.9B 5.45B 369B 5.57B 37.94B 15.25B 195B 14.65B 14.34B 618B 4.58B 4.08B 3.74B 3.4B 6.4B 434B 6.54B 44.55B 17.9B 229B 17.2B 16.83B 726B
Net income 777M 692M 635M 577M 1.09B 73.52B 1.11B 7.55B 3.03B 38.87B 2.92B 2.85B 123B 1.05B 931M 855M 777M 1.46B 99.01B 1.49B 10.17B 4.09B 52.34B 3.93B 3.84B 166B
Net Debt -1.67B -1.49B -1.37B -1.24B -2.34B -158B -2.39B -16.27B -6.54B -83.71B -6.28B -6.15B -265B -3B -2.67B -2.45B -2.23B -4.19B -284B -4.28B -29.16B -11.72B -150B -11.26B -11.02B -475B
Projected Income Statement - Annual - Neurocrine Biosciences, Inc.
Logo Neurocrine Biosciences, Inc.
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. It is engaged in discovering, developing, and commercializing life-changing treatments for patients with under-addressed neurological, psychiatric, endocrine, and immunological disorders. Its diverse portfolio includes the United States Food and Drug Administration-approved treatments for tardive dyskinesia, chorea associated with Huntington’s disease, endometriosis and uterine fibroids, as well as a robust pipeline, including multiple compounds in mid-to late-phase clinical development across its core therapeutic areas. Its first-in-class commercial portfolio includes INGREZZA (valbenazine) and CRENESSITY (crinecerfont). It also offers VYKAT XR (diazoxide choline) extended-release tablets, for the treatment of hyperphagia in adults and pediatric patients four years of age and older with Prader-Willi syndrome (PWS). Its pipeline includes direclidine / (M4 Agonist), osavampator॥ / (AMPA PAM) and others.
Employees
2,500
Date Price Change Volume
04/11/26 $166.05 +0.73% 2,220,210
03/11/26 $164.85 +13.42% 4,057,212
02/11/26 $145.35 -0.51% 2,018,496
30/10/26 $146.10 -0.19% 1,322,280
29/10/26 $146.38 +0.58% 831,120
Trader
Investor
Global
Quality
ESG MSCI
BBB
MarketScreener Ratings - Neurocrine Biosciences, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
29
Last Close Price
166.05USD
Average target price
207.50USD
Spread / Average Target
+24.96%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Neurocrine Biosciences, Inc.
  1. Stock Market
  2. Stocks
  3. NBIX Stock